Thromb Haemost 2001; 86(01): 57-65
DOI: 10.1055/s-0037-1616201
Research Article
Schattauer GmbH

Physiopathology and Regulation of Factor XIII

Akitada Ichinose
1   Department of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Yamagata, Japan
› Author Affiliations
Further Information

Publication History

Publication Date:
12 December 2017 (online)

Summary

Factor XIII is a plasma transglutaminase. Transglutaminases are at least 8 enzymes which cross-link a number of proteins. This type of reaction not only enhances the original functions of substrate proteins, but also adds new functions to them. Factor XIII in plasma is a tetramer (A2B2), and the A subunit contains the active site. Although transglutaminases are homologous, the nucleotide sequences in their 5’-flanking region differ significantly. Accordingly, transcription factors play a major role in the cell type-specific expression of each transglutaminase. A variety of missense and nonsense mutations, and deletions/insertions with or without out-of-frame shift/premature termination and splicing abnormalities have been identified in the genes for A and B subunits in factor XIII deficiency. In some cases, the mRNA level of the A or B subunit was severely reduced. Molecular and cellular bases have also been explored by expression experiments and by molecular modeling. In most cases, impaired folding and/or conformational change of the mutant A or B subunit leads to both intra- and extra-cellular instability, which is responsible for factor XIII deficiency.

 
  • References

  • 1 Ichinose A, Bottenus RE, Davie EW. Structure of transglutaminases. J Biol Chem 1990; 265: 13411-4.
  • 2 Candi E, Melino G, Mei G, Tarcsa E, Chung SI, Marekov LN, Steinert PM. Biochemical, structural, and transglutaminase substrate properties of human loricrin, the major epidermal cornified cell envelope protein. J Biol Chem 1995; 270: 26382-90.
  • 3 Fesus L, Madi A, Balajthy Z, Nemes Z, Szondy T. Transglutaminase induction by various cell death and apoptosis pathways. Experientia 1996; 52: 942-9.
  • 4 Lorand L, Losowsky MS, Miloszewski KJ. Human factor XIII: fibrin-stabilizing factor. Prog Hemost Thromb 1980; 5: 245-90.
  • 5 Ichinose A, Hendrickson LE, Fujikawa K, Davie EW. Amino acid sequence of the a subnunit of human factor XIII. Biochem 1986; 25: 6900-6.
  • 6 Ichinose A, McMullen BA, Fujikawa K, Davie EW. Amino acid sequence of the B subunit of human factor XIII, a protein composed of ten repetitive segments. Biochem 1986; 25: 4633-8.
  • 7 Ikura K, Nasu T, Yokota H, Tsuchiya Y, Sasaki R, Chiba H. Amino acid sequence of guinea pig liver transglutaminase from its cDNA sequence. Biochem 1988; 27: 2898-905.
  • 8 Tokunaga F, Muta T, Iwanaga S, Ichinose A, Davie EW, Kuma K, Miyata T. Limulus hemocyte transglutaminase. cDNA cloning, amino acid sequence, and tissue localization. J Biol Chem 1993; 268: 262-8.
  • 9 Korsgren C, Lawler J, Lambert S, Speicher D, Cohen CM. Complete amino acid sequence and homologies of human erythrocyte membrane protein band 4.2. Proc Natl Acad Sci USA 1990; 87: 613-7.
  • 10 Carrell NA, Erickson HP, McDonagh J. Electron microscopy and hydrodynamic properties of factor XIII subunits. J. Biol Chem 1989; 264: 551-6.
  • 11 Yee VC, Pedersen LC, Le Trong I, Bishop PD, Stenkamp RE, Teller DC. Three-dimensional structure of a transglutaminase: human blood coagulation factor XIII. Proc Natl Acad Sci USA 1994; 91: 7296-300.
  • 12 Yee VC, Pedersen LC, Bishop PD, Stenkamp RE, Teller DC. Structural evidence that the activation peptide is not released upon thrombin cleavage of factor XIII. Thromb Res 1995; 78: 389-97.
  • 13 Kurochkin IV, Procyk RPD, Yee VC, Teller DC, Ingham KC, Medved LV. Domain structure, stability and domain-domain interactions in recombinant factor XIII. J Mol Biol 1995; 248: 414-30.
  • 14 Weiss MS, Metzner HJ, Hilgenfeld R. Two non-proline cis peptide bonds may be important for factor XIII function. FEBS Lett 1998; 423: 291-6.
  • 15 Sadasivan C, Yee VC. Interaction of the factor XIII activation peptide with alpha-thrombin: crystal structure of its enzyme-substrate analog complex. J Biol Chem 2000; 275: 36942-8.
  • 16 Ichinose A, Davie EW. Characterization of the gene for the a subunit of human factor XIII (plasma transglutaminase), a blood coagulation factor. Proc Natl Acad Sci USA 1988; 85: 5829-33.
  • 17 Korsgren C, Cohen CM. Organization of the gene for human erythrocyte membrane protein 4.2: structural similarities with the gene for the a subunit of factor XIII. Proc Natl Acad Sci USA 1991; 88: 4840-4.
  • 18 Phillips MA, Stewart BE, Rice RH. Genomic structure of keratinocyte transglutaminase. Recruitment of new exon for modified function. J Biol Chem 1992; 267: 2282-6.
  • 19 Yamanishi K, Inazawa J, Liew FM, Nonomura K, Ariyama T, Yasuno H, Abe T, Doi H, Hirano J, Fukushima S. Structure of the gene for human transglutaminase 1. J Biol Chem 1992; 267: 17858-63.
  • 20 Kim IG, McBride OW, Wang M, Kim SY, Idler WW, Steinert PM. Structure and organization of the human transglutaminase 1 gene. J Biol Chem 1992; 267: 7710-7.
  • 21 Kim IG, Lee SC, Lee JH, Yang JM, Chung SI, Steinert PM. Structure and organization of the human transglutaminase 3 gene: evolutionary relationship to the transglutaminase family. J Invest Dermatol 1994; 103: 137-42.
  • 22 Fraij BM, Gonzales RA. Organization and structure of the human tissue transglutaminase gene. Biochim Biophys Acta 1997; 1354: 65-71.
  • 23 Board PG, Webb GC, McKee J, Ichinose A. Localization of the coagulation factor XIII A subunit gene (F13A) to chromosome bands 6p24-p25. Cytogenet Cell Genet 1988; 48: 25-7.
  • 24 Gentile V, Davies PJ, Baldini A. The human tissue transglutaminase gene maps on chromosome 20q12 by in situ fluorescence hybridization. Genomics 1994; 20: 295-7.
  • 25 Gentile V, Grant FJ, Porta R, Baldini A. Localization of the human prostate transglutaminase (type IV) gene (TGM4) to chromosome 3p21.33-p22 by fluorescence in situ hybridization. Genomics 1995; 27: 219-20.
  • 26 Bottenus RE, Ichinose A, Davie EW. Nucleotide sequence of the gene for the B subunit of human factor XIII. Biochemistry 1990; 29: 11195-209.
  • 27 Webb GC, Coggan M, Ichinose A, Board PG. Localization of the coagulation factor XIII B subunit gene (F13B) to chromosome bands 1q31-32.1 and restriction fragment length polymorphism at the locus. Hum Genet 1989; 81: 157-60.
  • 28 Rodriguez de Cordoba S, Rey-Campos J, Dykes DD, McAlpine PJ, Wong P, Rubinstein P. Coagulation factor XIII B subunit is encoded by a gene linked to the regulator of complement activation (RCA) gene cluster in man. Immunogenetics 1988; 28: 452-4.
  • 29 Pardo-Manuel F, Rey-Campos J, Hillarp A, Dahlback B, Rodriguez de Cordoba S. Human genes for the alpha and beta chains of complement C4b-binding protein are closely linked in a head-to-tail arrangement. Proc Natl Acad Sci USA 1990; 87: 4529-32.
  • 30 Grundmann U, Amann E, Zettlmeissl G, Kupper HA. Characterization of cDNA coding for human factor XIIIa. Proc Natl Acad Sci USA 1986; 83: 8024-8.
  • 31 Weisberg LJ, Shiu DT, Greenberg CS, Kan YW, Shuman MA. Localization of the gene for coagulation factor XIII a-chain to chromosome 6 and identification of sites of synthesis. J Clin Invest 1987; 79: 649-52.
  • 32 Kida M, Souri M, Yamamoto M, Saito H, Ichinose A. Transcriptional regulation of cell type-specific expression of the TATA-less A subunit gene for human coagulation factor XIII. J Biol Chem 1999; 274: 6138-47.
  • 33 Mariniello L, Qin Q, Jessen BA, Rice RH. Keratinocyte transglutaminase promoter analysis. Identification of a functional response element. J Biol Chem 1995; 270: 31358-63.
  • 34 Lu S, Saydak M, Gentile V, Stein JP, Davies PJ. Isolation and characterization of the human tissue transglutaminase gene promoter. J Biol Chem 1995; 270: 9748-56.
  • 35 Lee JH, Jang SI, Yang JM, Markova NG, Steinert PM. The proximal promoter of the human transglutaminase 3 gene. Stratified squamous epithelial-specific expression in cultured cells is mediated by binding of Sp1 and ets transcription factors to a proximal promoter element. J Biol Chem 1996; 271: 4561-8.
  • 36 Yamada K, Matsuki M, Morishima Y, Ueda E, Tabata K, Yasuno H, Suzuki M, Yamanishi K. Activation of the human transglutaminase 1 promoter in transgenic mice: terminal differentiation-specific expression of the TGM1-lacZ transgene in keratinized stratified squamous epithelia. Hum Mol Genet 1997; 6: 2223-31.
  • 37 Ariens RA, Kohler HP, Mansfield MW, Grant PJ. Subunit antigen and activity levels of blood coagulation factor XIII in healthy individuals. Relation to sex, age smoking, and hypertension. Arterioscl Thromb Vasc Biol 1999; 19: 2012-6.
  • 38 Nagy JA, Henriksson P, McDonagh J. Biosynthesis of factor XIII B subunit by human hepatoma cell lines. Blood 1986; 68: 1272-9.
  • 39 Wolpl A, Lattke H, Board PG, Arnold R, Schmeister T, Kubanek B, Robin-Winn M, Pichelmayr R, Goldmann SF. Coagulation factor XIII A and B subunits in bone marrow and liver transplantation. Transplantation 1987; 43: 151-3.
  • 40 Naidu YM, Rosen EM, Zitnick R, Goldberg I, Park M, Naujokas M, Polverini PJ, Nicholoff BJ. Role of scatter factor in the pathogenesis of AIDS-related Kaposi sarcoma. Proc Natl Acad Sci USA 1994; 91: 5281-5.
  • 41 Nickoloff BJ, Griffiths CE. Factor XIIIa-expressing dermal dendrocytes in AIDS-associated cutaneous Kaposi’s sarcomas. Science 1989; 243: 1736-7.
  • 42 Okamoto M, Yamamoto T, Matsubara S, Kukita I, Takeya M, Miyauchi Y, Kambara T. Factor XIII-dependent generation of 5th complement component(C5)-derived monocyte chemotactic factor coinciding with plasma clotting. Biochim Biophys Acta 1992; 1138: 53-61.
  • 43 Nishiura H, Shibuya Y, Matsubara S, Tanase S, Kambara T, Yamamoto T. Monocyte chemotactic factor in rheumatoid arthritis synovial tissue. Probably a cross-linked derivative of S19 ribosomal protein. J Biol Chem 1996; 271: 878-82.
  • 44 Vrij AA, Rijken J, van Wersch JW, Stockbrugger RW. Differential behavior of coagulation factor XIII in patients with inflammatory bowel disease and in patients with giant cell arteritis. Haemostasis 1999; 29: 326-35.
  • 45 D’Argenio G, Grossman A, Cosenza V, Valle ND, Mazzacca G, Bishop PD. Recombinant factor XIII improves established experimental colitis in rats. Dig Dis Sci 2000; 45: 987-97.
  • 46 Yamada T, Yoshiyama Y, Kawaguchi N, Ichinose A, Iwaki T, Hirose S, Jefferies WA. Possible roles of transglutaminases in Alzheimer’s disease. Dementia and Geriatric Cognitive Disorders 1998; 9: 103-10.
  • 47 Miller ML, Johnson GV. Transglutaminase cross-linking of the tau protein. J Neurochem 1995; 65: 1760-70.
  • 48 Ichinose A, Izumi T, Hashiguchi T. The normal and abnormal genes of the A and B subunits in coagulation factor XIII. Semin Thromb Hemost 1996; 22: 385-91.
  • 49 Takahashi N, Takahashi Y, Putnam FW. Primary structure of blood coagulation factor XIIIa (fibrinoligase, transglutaminase) from human placenta. Proc Natl Acad Sci USA 1986; 83: 8019-23.
  • 50 Kohler HP, Stickland MH, Ossei-Gerning N, Carter A, Mikkola H, Grant PJ. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost 1998; 79: 8-13.
  • 51 Elbaz A, Poirier O, Canaple S, Chedru F, Cambien F, Amarenco P. The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction. Blood 2000; 95: 586-91.
  • 52 Ariens RA, Phillippou H, Nagaswami C, Weisel JW, Lane DA, Grant PJ. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 2000; 96: 988-95.
  • 53 Balogh I, Szoke G, Karpati L, Wartiovaara U, Katona E, Komaromi I, Haramura G, Pfliegler G, Mikkola H, Muszbek L. Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophilia. Blood 2000; 96: 2479-86.
  • 54 Trumbo TA, Maurer MC. Examining thrombin hydrolysis of the factor XIII activation peptide segment leads to a proposal for explaining the cardioprotective effects observed with the factor XIII V34L mutation. J Biol Chem 2000; 275: 20627-31.
  • 55 Asahina T, Kobayashi T, Okada Y, Goto J, Terao T. Maternal blood coagulation factor XIII is associated with the development of cytotrophoblastic shell. Placenta 2000; 21: 388-93.
  • 56 Girolami A, Burul A, Fabris F, Cappelato G, Betterle C. Studies of factor XIII antigen in congenital factor XIII deficiency. A tentative classification of the disease in two groups. Folia Haematol 1978; 105: 131-41.
  • 57 Capellato MG, Lazzaro AR, Marafioti F, Polato G, Girolami A. A new family with congenital factor XIII deficiency showing a deficit of both subunit A and B. Type I factor XIII deficiency. Haematologia 1987; 20: 179-87.
  • 58 Saito M, Asakura H, Yoshida T, Ito K, Okafuji K, Yoshida T, Matsuda T. A familial factor XIII subunit B deficiency. Br J Haematol 1990; 74: 290-4.
  • 59 Rodeghiero F, Tosetto A, Di Bona E, Castaman G. Clinical pharmacokinetics of a placenta-derived factor XIII concentrate in type I and type II factor XIII deficiency. Am J Hematol 1991; 36: 30-4.
  • 60 Ichinose A, Souri M, Izumi T, Takahashi N. Molecular and genetic mechanisms of factor XIII A subunit deficiency. Semin Thromb Hemost 2000; 26: 5-10.
  • 61 Ichinose A, Kaetsu H. Molecular approach to structure-function relationship of human coagulation factor XIII. Method Enzymol 1993; 222: 36-51.
  • 62 Anwar R, Miloszewski KJ. Factor XIII deficiency. Br J Haematol 1999; 107: 468-84.
  • 63 Anwar R, Miloszewski KJ, Markham AF. Identification of a large deletion, spanning exons 4 to 11 of the human factor XIIIA gene, in a factor XIII-deficient family. Blood 1998; 91: 149-53.
  • 64 Coggan M, Baker R, Miloszewski K, Woodfield G, Board P. Mutations causing coagulation factor XIII subunit A deficiency: characterization of the mutant proteins after expression in yeast. Blood 1995; 85: 2455-60.
  • 65 Mikkola H, Muszbek L, Haramura G, Hamalainen E, Jalanko A, Palotie A. Molecular mechanisms of mutations in factor XIII A-subunit deficiency: in vitro expression in COS-cells demonstrates intracellular degradation of the mutant proteins. Thromb Haemost 1997; 77: 1068-72.
  • 66 Takahashi N, Tsukamoto H, Umeyama H, Castaman G, Rodeghiero F, Ichinose A. Molecular mechanisms of type II factor XIII deficiency: novel Gly562-Arg mutation and C-terminal truncation of the A subunit cause factor XIII deficiency as characterized in a mammalian expression system. Blood 1998; 91: 2830-8.
  • 67 Kangsadalampai S, Chelvanayagam G, Baker RT, Yenchitsomanus P, Pung-Amritt P, Mahasandana C, Board PG. A novel Asn344 deletion in the core domain of coagulation factor XIII A subunit: its effects on protein structure and function. Blood 1998; 92: 481-7.
  • 68 Kangsadalampai S, Chelvanayagam G, Baker R, Tiedemann K, Kuperan P, Board PG. Identification and characterization of two missense mutations causing factor XIIIA deficiency. Br J Haematol 1999; 104: 37-43.
  • 69 Ichinose A, Tsukamto H, Izumi T, Yamazaki T, Togashi M, Takamatsu J, Saito H, Umeyama H. Arg260-Cys mutation in severe factor XIII deficiency: conformational change of the A subunit is predicted by molecular modelling and mechanics. Br J Haematol 1998; 101: 264-72.
  • 70 Izumi T, Nagaoka U, Saito T, Takamatsu J, Saito H, Ichinose A. Novel deletion and insertion mutations cause splicing defects, leading to severe reduction in mRNA levels of the A subunit in severe factor XIII deficiency. Thromb Haemost 1998; 79: 479-85.
  • 71 Anwar R, Stewart AD, Miloszewski KJ, Losowsky MS, Markham AF. Molecular basis of inherited factor XIII deficiency: identification of multiple mutations provides insights into protein function. Br J Haematol 1995; 91: 728-35.
  • 72 Mikkola H, Muszbek L, Laiho E, Syrjala M, Hamalainen E, Haramura G, Salmi T, Peltonen L, Palotie A. Molecular mechanism of a mild phenotype in coagulation factor XIII (FXIII) deficiency: a splicing mutation permitting partial correct splicing of FXIII A-subunit mRNA. Blood 1997; 89: 1279-87.
  • 73 Hashiguchi T, Saito M, Morishita E, Matsuda T, Ichinose A. Two genetic defects in a patient with complete deficiency of the b-subunit for coagulation factor XIII. Blood 1993; 82: 145-50.
  • 74 Hashiguchi T, Ichinose A. Molecular and cellular basis of deficiency of the B subunit for factor XIII secondary to a Cys430-Phe mutation in the seventh Sushi domain. J Clin Invest 1995; 95: 1002-8.
  • 75 Izumi T, Hashiguchi T, Castaman G, Tosetto A, Rodeghiero F, Girolami A, Ichinose A. Type I factor XIII deficiency is caused by a genetic defect of its B subunit: insertion of triplet AAC in exon III leads to premature termination in the second Sushi domain. Blood 1996; 87: 2769-74.
  • 76 Souri M, Izumi T, Higashi Y, Girolami A, Ichinose A. A Founder effect is proposed for Factor XIII B subunit deficiency caused by the insertion of triplet AAC in exon III encoding the second sushi domain. Thromb Haemost 1998; 80: 211-3.
  • 77 Koseki S, Souri M, Koga S, Yamakawa M, Shitishima T, Maruyama Y, Yanai F, Ichinose A. Truncated mutant B subunit for Factor XIII causes its deficiency due to impaired intracellular transportation. Blood. in press.
  • 78 Kaetsu H, Hashiguchi T, Foster D, Ichinose A. Expression and release of the A and B subunits for human coagulation factor XIII in baby hamster kidney (BHK) cells. J Biochem 1996; 119: 961-9.